Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 Ordinary Shares in an open-market transaction at a weighted average price of $5.2354 per share. Following the sale, he directly holds 3,620,995 shares.
The sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The shares were sold in multiple trades at prices ranging from $5.13 to $5.42.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza bought 20,000 Ordinary Shares in an open-market purchase at $4.95 per share. After this transaction, he directly holds 311,458 Ordinary Shares. The purchase was made during an open trading window under the company’s insider trading policy.
SOPHiA GENETICS filed a Form 6-K highlighting a new Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to work toward forming a joint venture focused on precision oncology. The envisioned precision medicine hub would combine MSK’s extensive clinical data and expertise with SOPHiA GENETICS’s Ai-driven SOPHiA DDM™ platform.
The collaboration aims to discover, develop, and deploy next-generation precision oncology solutions for patients worldwide and create infrastructure for biopharma companion diagnostics and clinical algorithms. The agreement is currently an MOU, and detailed terms of the strategic initiative have not yet been finalized.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.9548 per share. The transaction was executed on May 26, 2026 pursuant to a duly adopted Rule 10b5-1(c) trading plan.
After this sale, Menu directly holds 250,780 Ordinary Shares, indicating he retains a substantial equity position in the company. The sale price reflects multiple trades within a range of $4.78 to $5.01 per share, aggregated into the reported weighted average.
SOPHiA GENETICS SA President Ross Muken reported a small open-market sale of 761 Ordinary Shares at a weighted average price of $4.6006 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.
The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. After the transaction, Muken directly holds 680,911 Ordinary Shares, indicating this was a minor, routine tax-related disposition relative to his overall position.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares. The shares were sold at a weighted average price of $4.6015 per share on May 19, 2026, to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026.
According to the disclosure, these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. Following this transaction, Xu directly holds 626,280 Ordinary Shares.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 Ordinary Shares in an open-market transaction at a weighted average price of $4.6049 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.
The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this transaction, Camblong directly holds 3,629,495 Ordinary Shares.
SOPHiA GENETICS SA’s Chief Medical Officer, Philippe Menu, sold 608 Ordinary Shares of the company on May 19, 2026 at a weighted average price of $4.6059 per share. According to the disclosure, these shares were sold in the open market solely to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary. Following this sale, Menu directly holds 255,780 Ordinary Shares.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported an open-market sale of 684 Ordinary Shares at a weighted average price of $4.6042 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations from vesting restricted stock units under a pre-established Rule 10b5-1(c) trading plan and was not discretionary. Following this transaction, Van Well directly holds 345,052 Ordinary Shares.
SOPHiA GENETICS SA’s Chief People Officer, Manuela Valente, reported a small tax-related share sale. On May 19, 2026, she sold 380 Ordinary Shares at a weighted average price of $4.5985 per share, in open-market transactions.
The footnotes explain that these shares were sold solely to cover tax withholding obligations from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, she directly holds 214,691 Ordinary Shares.